Table 2 Incidence rates of adverse events (AEs) and premature discontinuation.
From: Evaluation of vardenafil for the treatment of subjective tinnitus: a controlled pilot study
Vardenafil (N = 21) | Placebo (N = 21) | |
|---|---|---|
Treatment-emergent AEs | 8 (38.1%) | 3 (14.3%) |
Drug-related AEs | 6 (28.5%) | 2 (9.5%) |
- Headache | 1 (4.75%) | 2 (9.5%) |
- Diarrhea | 2 (9.5%) | 0 (0%) |
- Nasal congestion | 2 (9.5%) | 0 (0%) |
- Prolonged penile erection | 1 (4.75%) | 0 (0%) |
Serious or fatal AEs | 0 (0%) | 0 (0%) |
Premature discontinuation | 5 (23.8%) | 2 (9.5%) |
- due to drug-related AEs | 4 (19.05%) | 1 (4.75%) |
- due to poor compliance | 1 (4.75%) | 1 (4.75%) |